Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Colin Smith
  • Colin Smith

Tullow Oil | Initiation: Deleveraging targets well within sight

Tullow operates the Jubilee and TEN oil fields offshore Ghana and has just announced the sale of its Gabonese assets for US$300m. Current production and reserves are a substantial c55kboed and 165mmboe, including Gabon. Following a disciplined re-focusing of the business and the sale of its Gabonese assets, the company's de-leveraging targets of net debt under US$1bn and leverage under 1x are well within sight with further options to accelerate the process. Tullow has now returned to sustained p...

Colin Smith
  • Colin Smith

Polarean Imaging | Investor update presentation confirms thesis

Polarean held a presentation for investors to recap the investment thesis for its unique technology for visualising lung function and provide real life examples of its Xenon MRI imaging in both research and clinical use. Dr Alan Huang, recently appointed VP Global Sales, provided a positive update on the sales pipeline and process. Polarean reaffirmed existing guidance. However, while there was no new news, the presentation certainly helped demonstrate the enthusiasm with which Polarean's techno...

Colin Smith
  • Colin Smith

Craneware Group | 1H25 results – Return to double digit growth

Further to the company's interim trading update, the 10% growth in revenue and adjusted EBITDA translated into an even more impressive increase in adjusted profit before tax of 21% to US$20.6m and an 18% increase in adjusted EPS. Operating cash conversion hit 110% and period end net cash jumped to US$40.6m. Management report that positive trading has continued into the second half of the year and the Board remains confident in achieving results for the year to June 2025 in line with current mark...

Colin Smith
  • Colin Smith

Polarean Imaging | Xenon MRI pharma research collaboration

Polarean has announced that its Xenon MRI lung imaging has been selected by a leading global pharma company to be included in a clinical trial due to start in 4Q25. This collaboration opens up a new vertical for Polarean but more importantly provides third party validation of the unmatched lung imaging that Polarean's Xenon MRI system provides. Polarean recently announced a better than expected update for FY24 which, in our view, confirms that the company is on the cusp of hyperbolic growth with...

Colin Smith
  • Colin Smith

Galliford Try | 1HFY25 results – Increased confidence in FY25

Further to its positive trading update, Galliford Try has delivered another excellent set of results for the half to December underlined by a 37.5% hike in the interim dividend to 5.5p. The company announced adjusted PBT for 1HFY25 of £20.5m, up 22.0% YoY. Despite the increase in consensus forecasts following the trading statement, management now expect revenue and adjusted PBT to be above the top end of the range of market forecasts which currently stand at £1,835m and £36.0m, respectively. Rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch